DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3203-348-358$20.00
DMD 32:348-358, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faucette, S. R.
Right arrow Articles by LeCluyse, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faucette, S. R.
Right arrow Articles by LeCluyse, E. L.

REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS

Stephanie R. Faucette, Hongbing Wang, Geraldine A. Hamilton, Summer L. Jolley, Darryl Gilbert, Celeste Lindley, Bingfang Yan, Masahiko Negishi, and Edward L. LeCluyse

Divisions of Drug Delivery and Disposition (S.R.F., H.W., G.A.H., S.L.J., D.G., E.L.L.) and Pharmacotherapy (C.L.), School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Biomedical Sciences, University of Rhode Island, Kingston, Rhode Island (B.Y.); and Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (M.N.)

The objectives of this study were to evaluate the ability of 14 compounds, which differentially activate human pregnane X receptor (hPXR), to induce CYP2B6 expression and to compare CYP2B6 and CYP3A4 concentration- and time-dependent induction by select inducers. Three primary human hepatocyte preparations were treated daily for 3 days with three concentrations of all compounds. Additional concentration- and/or time-response studies were conducted with clotrimazole, phenytoin, phenobarbital, and rifampin in six preparations. CYP2B6 and CYP3A4 protein and activities were assessed by Western blotting, bupropion hydroxylation, and testosterone 6ß-hydroxylation, respectively. To evaluate hPXR activation by the 14 compounds, reporter gene assays were conducted using Huh7 cells cotransfected with hPXR and a CYP2B6 (NR1)5-LUC reporter plasmid. Clotrimazole, phenobarbital, rifampin, and ritonavir strongly induced CYP2B6 and activated hPXR; dexamethasone t-butylacetate and sulfinpyrazone induced CYP2B6 weakly and activated hPXR moderately; paclitaxel strongly activated hPXR but did not increase CYP2B6 expression; carbamazepine and phenytoin moderately or strongly increased CYP2B6 expression but weakly activated hPXR; and dexamethasone, methotrexate, probenecid, sulfadimidine, and troleandomycin demonstrated weak or negligible effects on CYP2B6 and hPXR. EC50 values for CYP2B6 and CYP3A4 induction by clotrimazole, phenobarbital, phenytoin, and rifampin were strongly correlated (r2 = 0.99) and were statistically indistinguishable for clotrimazole, phenytoin, and rifampin. Kinetic constants governing time-dependent induction by phenobarbital and rifampin were also similar between CYP2B6 and CYP3A4. These results indicate that CYP2B6 is highly inducible by known CYP3A4 inducers and suggest that hPXR is a major determinant of CYP2B6-inducible expression for many, but not all, compounds evaluated in this study.


Address correspondence to: Dr. Edward L. LeCluyse, Division of Drug Delivery and Disposition, School of Pharmacy, CB #7360, Kerr Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: ed_lecluyse{at}unc.edu




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
A. Kwara, M. Lartey, K. W. Sagoe, F. Xexemeku, E. Kenu, J. Oliver-Commey, V. Boima, A. Sagoe, I. Boamah, D. J. Greenblatt, et al.
Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation
J. Clin. Pharmacol., September 1, 2008; 48(9): 1032 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Gupta, G. M. Mugundu, P. B. Desai, K. E. Thummel, and J. D. Unadkat
Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors
Drug Metab. Dispos., June 1, 2008; 36(6): 1172 - 1180.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco
Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma
Neuro-oncol, April 1, 2008; 10(2): 190 - 198.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
E. D. Kharasch, D. Mitchell, and R. Coles
Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity
J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. Vuppugalla, S.-Y. Chang, H. Zhang, P. H. Marathe, and D. A. Rodrigues
Effect of Commonly Used Organic Solvents on the Kinetics of Cytochrome P450 2B6- and 2C8-Dependent Activity in Human Liver Microsomes
Drug Metab. Dispos., November 1, 2007; 35(11): 1990 - 1995.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. P. Hernandez, W. Huang, L. M. Chapman, S. Chua, D. D. Moore, and W. S. Baldwin
The Environmental Estrogen, Nonylphenol, Activates the Constitutive Androstane Receptor
Toxicol. Sci., August 1, 2007; 98(2): 416 - 426.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. A. Totah, K. E. Allen, P. Sheffels, D. Whittington, and E. D. Kharasch
Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 389 - 399.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. R. Faucette, T.-C. Zhang, R. Moore, T. Sueyoshi, C. J. Omiecinski, E. L. LeCluyse, M. Negishi, and H. Wang
Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 72 - 80.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. L. Walsky, A. V. Astuccio, and R. S. Obach
Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6.
J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko
The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride
Clin. Cancer Res., September 1, 2006; 12(17): 5174 - 5181.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. F. McGinnity, A. J. Berry, J. R. Kenny, K. Grime, and R. J. Riley
EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES
Drug Metab. Dispos., August 1, 2006; 34(8): 1291 - 1300.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. R. Faucette, T. Sueyoshi, C. M. Smith, M. Negishi, E. L. LeCluyse, and H. Wang
Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1200 - 1209.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court
Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.
J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. S. Auerbach, M. A. Stoner, S. Su, and C. J. Omiecinski
Retinoid X Receptor-{alpha}-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3)
Mol. Pharmacol., November 1, 2005; 68(5): 1239 - 1253.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al.
EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES
Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Giraud, A. Tran, E. Rey, J. Vincent, J.-M. Treluyer, and G. Pons
IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
Drug Metab. Dispos., November 1, 2004; 32(11): 1279 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang, S. Faucette, R. Moore, T. Sueyoshi, M. Negishi, and E. LeCluyse
Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin
J. Biol. Chem., July 9, 2004; 279(28): 29295 - 29301.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.